CABOTRIM 2

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

CABERGOLINE

متاح من:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD

ATC رمز:

N04BC06

الشكل الصيدلاني:

TABLETS

تركيب:

CABERGOLINE 2 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD, ISRAEL

المجموعة العلاجية:

CABERGOLINE

المجال العلاجي:

CABERGOLINE

الخصائص العلاجية:

Parkinson's disease. Combination therapy with L-dopa and as monotherapy for newly diagnosed illness.

تاريخ الترخيص:

2014-06-30

نشرة المعلومات

∙ you are suffering from low blood pressure and/or are being treated
with antihypertensives.
∙ you took pergolide in the past.
SPECIAL WARNINGS REGARDING USE OF THE MEDICINE:
∙ If you are sensitive to any food or medicine, inform the doctor
before
taking the medicine.
∙ Before using the medicine, tests to rule out pregnancy should be
performed. While using the medicine, nonhormonal contraceptive
methods should be used. In case of pregnancy, stop taking the
medicine immediately. Prevent pregnancy for at least one month
after completing use of the medicine.
∙ Especially in the first days of treatment low blood pressure may
develop.
∙ The preparation belongs to a group of medicines which might cause
the following effects: addictive gambling, overspending, compulsive
eating, increased libido and hypersexuality. These effects generally
subside upon reduction of the dosage or treatment modification by
the doctor.
∙ In certain cases, long-term treatment with cabergoline may cause
fibrosis and inflammatory conditions of the lungs, pericardium and
the retroperitoneum as well as cardiac valve damage. In some cases,
cardiac valve damage improves upon cessation of treatment with
cabergoline. Patients who are taking cabergoline and experience
breathing disturbances or difficulties, are advised to refer to the
doctor
who will consider performing a chest x-ray, blood sedimentation and/
or serum creatinine measurement.
∙ During treatment with the preparation, refer to a doctor
immediately
if you experience the following signs: difficulty breathing, shortness
of breath, prolonged cough and/or chest pains, pains and swelling
in the waist area and/or heart failure. TESTS THAT SHOULD BE PERFORMED BEFORE USING THE MEDICINE:
∙ Before using the medicine, tests to rule out pregnancy should be
performed.
∙ The patient must undergo cardiovascular evaluation including an
echocardiogram. It is also recommended to perform, before starting
the treatment, blood sedimentation test, lung function/chest x-ray
and kidney functi